Ontario-based Maricann is one step closer to cracking the German market as its recent shipment of dry cannabis flowers safely arrived in that country on Wednesday and met all specifications, the company said.
The announcement follows on the heels of its plan to start selling 25mg CBD gel caps next week through its European nutraceutical line of business, MariPlant.
The capsules deliver the CBD through a multi-patented delivery system called VESIsorb(R) and have been used by 200 million consumers on six continents, according to parent company Maricann Inc.
CEO Ben Ward said that the successful export this week “further validates the platform that (we) have built at Maricann, with EU-GMP certified cannabis flower exports from our facilities in Canada now a reality,” he said.
The cannabis producer and distributor is one of five companies with EU-GMP certified facilities for global cannabis production, positioning it to capture market share in the European medical market.
Maricann Inc. subsidiary Maricann Group received an export permit from Health Canada on April 16, 2018.
The company operates a medicinal cannabis cultivation, extraction, formulation and distribution business at its production facilities in Langton, Ontario.
It also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland.
Maricann shares ended the week up 8 per cent, with more than 825,000 shares changing hands.